 | • レポートコード：MRC2102QY9438 • 出版社/出版日： / 2021年1月 • レポート形態：英文、PDF、147ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品、医療 |
| Single User | ￥600,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥900,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,200,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYリサーチ社の本調査レポートでは、世界の多発性硬化症（MS）治療薬市場について種類別（コパキソン（酢酸グラチラマー・コポリマー1）、ノバントロン（ミトキサントロン）、ギレニア（フィンゴリモド・Fty720）、アウバジオ（テリフルノミド）、テクフィデラ（フマル酸ジメチル）、フィレートグラス（Sb683699・T-0047）、シポニモド（Baf312）、その他）、用途別（RRMS、SPMS、PPMS、PRMS）、地域別（米国、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・多発性硬化症（MS）治療薬市場の概要 ・世界の主要地域別多発性硬化症（MS）治療薬市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の多発性硬化症（MS）治療薬市場規模2015-2026：種類別（コパキソン（酢酸グラチラマー・コポリマー1）、ノバントロン（ミトキサントロン）、ギレニア（フィンゴリモド・Fty720）、アウバジオ（テリフルノミド）、テクフィデラ（フマル酸ジメチル）、フィレートグラス（Sb683699・T-0047）、シポニモド（Baf312）、その他） ・世界の多発性硬化症（MS）治療薬市場規模2015-2026：用途別（RRMS、SPMS、PPMS、PRMS） ・多発性硬化症（MS）治療薬の米国市場規模2015-2020 ・多発性硬化症（MS）治療薬のヨーロッパ市場規模2015-2020 ・多発性硬化症（MS）治療薬の中国市場規模2015-2020 ・多発性硬化症（MS）治療薬の日本市場規模2015-2020 ・多発性硬化症（MS）治療薬の東南アジア市場規模2015-2020 ・多発性硬化症（MS）治療薬のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 ・多発性硬化症（MS）治療薬の製造コスト分析 ・販売チャネル、流通業者、顧客 ・多発性硬化症（MS）治療薬の市場動向・機会・課題 ・調査の結論 |
Market Analysis and Insights: Global Multiple Sclerosis (MS) Drugs Market
The global Multiple Sclerosis (MS) Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
Global Multiple Sclerosis (MS) Drugs Scope and Market Size
The global Multiple Sclerosis (MS) Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Multiple Sclerosis (MS) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Multiple Sclerosis (MS) Drugs market is segmented into
Copaxone (Glatiramer Acetate, Copolymer 1)
Novantrone (Mitoxantrone)
Gilenya (Fingolimod, Fty720)
Aubagio (Teriflunomide)
Tecfidera (Dimethyl Fumarate)
Firategrast (Sb683699, T-0047)
Siponimod (Baf312)
Others
Segment by Application, the Multiple Sclerosis (MS) Drugs market is segmented into
RRMS
SPMS
PPMS
PRMS
The Multiple Sclerosis (MS) Drugs market is analysed and market size information is provided by regions (countries). Segment by Application, the Multiple Sclerosis (MS) Drugs market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Multiple Sclerosis (MS) Drugs Market Share Analysis
Multiple Sclerosis (MS) Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Multiple Sclerosis (MS) Drugs business, the date to enter into the Multiple Sclerosis (MS) Drugs market, Multiple Sclerosis (MS) Drugs product introduction, recent developments, etc.
The major vendors covered:
Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope
Five Prime Therapeutics
Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics
1 Multiple Sclerosis (MS) Drugs Market Overview
1.1 Multiple Sclerosis (MS) Drugs Product Scope
1.2 Multiple Sclerosis (MS) Drugs Segment by Type
1.2.1 Global Multiple Sclerosis (MS) Drugs Sales by Type (2020-2026)
1.2.2 Copaxone (Glatiramer Acetate, Copolymer 1)
1.2.3 Novantrone (Mitoxantrone)
1.2.4 Gilenya (Fingolimod, Fty720)
1.2.5 Aubagio (Teriflunomide)
1.2.6 Tecfidera (Dimethyl Fumarate)
1.2.7 Firategrast (Sb683699, T-0047)
1.2.8 Siponimod (Baf312)
1.2.9 Others
1.3 Multiple Sclerosis (MS) Drugs Segment by Application
1.3.1 Global Multiple Sclerosis (MS) Drugs Sales Comparison by Application (2020-2026)
1.3.2 RRMS
1.3.3 SPMS
1.3.4 PPMS
1.3.5 PRMS
1.4 Multiple Sclerosis (MS) Drugs Market Estimates and Forecasts (2015-2026)
1.4.1 Global Multiple Sclerosis (MS) Drugs Sales Growth Rate (2015-2026)
1.4.2 Global Multiple Sclerosis (MS) Drugs Revenue and Growth Rate (2015-2026)
1.4.3 Global Multiple Sclerosis (MS) Drugs Price Trends (2015-2026)
2 Multiple Sclerosis (MS) Drugs Estimate and Forecast by Region
2.1 Global Multiple Sclerosis (MS) Drugs Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Multiple Sclerosis (MS) Drugs Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2015-2020)
2.2.2 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2015-2020)
2.3 Global Multiple Sclerosis (MS) Drugs Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Multiple Sclerosis (MS) Drugs Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Multiple Sclerosis (MS) Drugs Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Multiple Sclerosis (MS) Drugs Estimates and Projections (2015-2026)
2.4.2 Europe Multiple Sclerosis (MS) Drugs Estimates and Projections (2015-2026)
2.4.3 China Multiple Sclerosis (MS) Drugs Estimates and Projections (2015-2026)
2.4.4 Japan Multiple Sclerosis (MS) Drugs Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Multiple Sclerosis (MS) Drugs Estimates and Projections (2015-2026)
2.4.6 India Multiple Sclerosis (MS) Drugs Estimates and Projections (2015-2026)
3 Global Multiple Sclerosis (MS) Drugs Competition Landscape by Players
3.1 Global Top Multiple Sclerosis (MS) Drugs Players by Sales (2015-2020)
3.2 Global Top Multiple Sclerosis (MS) Drugs Players by Revenue (2015-2020)
3.3 Global Multiple Sclerosis (MS) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Multiple Sclerosis (MS) Drugs as of 2019)
3.4 Global Multiple Sclerosis (MS) Drugs Average Price by Company (2015-2020)
3.5 Manufacturers Multiple Sclerosis (MS) Drugs Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Multiple Sclerosis (MS) Drugs Players (Opinion Leaders)
4 Global Multiple Sclerosis (MS) Drugs Market Size by Type
4.1 Global Multiple Sclerosis (MS) Drugs Historic Market Review by Type (2015-2020)
4.1.1 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
4.1.2 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2015-2020)
4.1.3 Global Multiple Sclerosis (MS) Drugs Price by Type (2015-2020)
4.2 Global Multiple Sclerosis (MS) Drugs Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Multiple Sclerosis (MS) Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Multiple Sclerosis (MS) Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Global Multiple Sclerosis (MS) Drugs Price Forecast by Type (2021-2026)
5 Global Multiple Sclerosis (MS) Drugs Market Size by Application
5.1 Global Multiple Sclerosis (MS) Drugs Historic Market Review by Application (2015-2020)
5.1.1 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2015-2020)
5.1.2 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2015-2020)
5.1.3 Global Multiple Sclerosis (MS) Drugs Price by Application (2015-2020)
5.2 Global Multiple Sclerosis (MS) Drugs Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Multiple Sclerosis (MS) Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Multiple Sclerosis (MS) Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Multiple Sclerosis (MS) Drugs Price Forecast by Application (2021-2026)
6 United States Multiple Sclerosis (MS) Drugs Market Facts & Figures
6.1 United States Multiple Sclerosis (MS) Drugs Sales Market Share by Company (2015-2020)
6.2 United States Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
6.3 United States Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2015-2020)
7 Europe Multiple Sclerosis (MS) Drugs Market Facts & Figures
7.1 Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Company (2015-2020)
7.2 Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
7.3 Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2015-2020)
8 China Multiple Sclerosis (MS) Drugs Market Facts & Figures
8.1 China Multiple Sclerosis (MS) Drugs Sales Market Share by Company (2015-2020)
8.2 China Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
8.3 China Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2015-2020)
9 Japan Multiple Sclerosis (MS) Drugs Market Facts & Figures
9.1 Japan Multiple Sclerosis (MS) Drugs Sales Market Share by Company (3015-3030)
9.2 Japan Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
9.3 Japan Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2015-2020)
10 Southeast Asia Multiple Sclerosis (MS) Drugs Market Facts & Figures
10.1 Southeast Asia Multiple Sclerosis (MS) Drugs Sales Market Share by Company (2015-2020)
10.2 Southeast Asia Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
10.3 Southeast Asia Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2015-2020)
11 India Multiple Sclerosis (MS) Drugs Market Facts & Figures
11.1 India Multiple Sclerosis (MS) Drugs Sales Market Share by Company (2015-2020)
11.2 India Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
11.3 India Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Multiple Sclerosis (MS) Drugs Business
12.1 Bayer AG
12.1.1 Bayer AG Corporation Information
12.1.2 Bayer AG Business Overview
12.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Bayer AG Multiple Sclerosis (MS) Drugs Products Offered
12.1.5 Bayer AG Recent Development
12.2 Bayhill Therapeutics
12.2.1 Bayhill Therapeutics Corporation Information
12.2.2 Bayhill Therapeutics Business Overview
12.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Products Offered
12.2.5 Bayhill Therapeutics Recent Development
12.3 Biogen Idec
12.3.1 Biogen Idec Corporation Information
12.3.2 Biogen Idec Business Overview
12.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Biogen Idec Multiple Sclerosis (MS) Drugs Products Offered
12.3.5 Biogen Idec Recent Development
12.4 Cinnagen
12.4.1 Cinnagen Corporation Information
12.4.2 Cinnagen Business Overview
12.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Cinnagen Multiple Sclerosis (MS) Drugs Products Offered
12.4.5 Cinnagen Recent Development
12.5 Daiichi Sankyo
12.5.1 Daiichi Sankyo Corporation Information
12.5.2 Daiichi Sankyo Business Overview
12.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Products Offered
12.5.5 Daiichi Sankyo Recent Development
12.6 Eli Lilly
12.6.1 Eli Lilly Corporation Information
12.6.2 Eli Lilly Business Overview
12.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Eli Lilly Multiple Sclerosis (MS) Drugs Products Offered
12.6.5 Eli Lilly Recent Development
12.7 Fast Forward Llc
12.7.1 Fast Forward Llc Corporation Information
12.7.2 Fast Forward Llc Business Overview
12.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Products Offered
12.7.5 Fast Forward Llc Recent Development
12.8 Antisense Therapeutics
12.8.1 Antisense Therapeutics Corporation Information
12.8.2 Antisense Therapeutics Business Overview
12.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Products Offered
12.8.5 Antisense Therapeutics Recent Development
12.9 Apitope
12.9.1 Apitope Corporation Information
12.9.2 Apitope Business Overview
12.9.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Apitope Multiple Sclerosis (MS) Drugs Products Offered
12.9.5 Apitope Recent Development
12.10 Five Prime Therapeutics
12.10.1 Five Prime Therapeutics Corporation Information
12.10.2 Five Prime Therapeutics Business Overview
12.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Products Offered
12.10.5 Five Prime Therapeutics Recent Development
12.11 Genmab
12.11.1 Genmab Corporation Information
12.11.2 Genmab Business Overview
12.11.3 Genmab Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Genmab Multiple Sclerosis (MS) Drugs Products Offered
12.11.5 Genmab Recent Development
12.12 Artielle Immunotherapeutics
12.12.1 Artielle Immunotherapeutics Corporation Information
12.12.2 Artielle Immunotherapeutics Business Overview
12.12.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Products Offered
12.12.5 Artielle Immunotherapeutics Recent Development
12.13 Genzyme
12.13.1 Genzyme Corporation Information
12.13.2 Genzyme Business Overview
12.13.3 Genzyme Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Genzyme Multiple Sclerosis (MS) Drugs Products Offered
12.13.5 Genzyme Recent Development
12.14 Glaxosmithkline
12.14.1 Glaxosmithkline Corporation Information
12.14.2 Glaxosmithkline Business Overview
12.14.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.14.4 Glaxosmithkline Multiple Sclerosis (MS) Drugs Products Offered
12.14.5 Glaxosmithkline Recent Development
12.15 Gw Pharmaceuticals
12.15.1 Gw Pharmaceuticals Corporation Information
12.15.2 Gw Pharmaceuticals Business Overview
12.15.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Products Offered
12.15.5 Gw Pharmaceuticals Recent Development
12.16 Innate Immunotherapeutics
12.16.1 Innate Immunotherapeutics Corporation Information
12.16.2 Innate Immunotherapeutics Business Overview
12.16.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.16.4 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Products Offered
12.16.5 Innate Immunotherapeutics Recent Development
13 Multiple Sclerosis (MS) Drugs Manufacturing Cost Analysis
13.1 Multiple Sclerosis (MS) Drugs Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs
13.4 Multiple Sclerosis (MS) Drugs Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Multiple Sclerosis (MS) Drugs Distributors List
14.3 Multiple Sclerosis (MS) Drugs Customers
15 Market Dynamics
15.1 Multiple Sclerosis (MS) Drugs Market Trends
15.2 Multiple Sclerosis (MS) Drugs Opportunities and Drivers
15.3 Multiple Sclerosis (MS) Drugs Market Challenges
15.4 Multiple Sclerosis (MS) Drugs Market Restraints
15.5 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Multiple Sclerosis (MS) Drugs Sales (K Pcs) Growth Rate by Type (2020-2026) (US$ Million)
Table 2. Global Multiple Sclerosis (MS) Drugs Sales (K Pcs) Comparison by Application (2020-2026) (US$ Million)
Table 3. Global Market Multiple Sclerosis (MS) Drugs Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Region (2015-2020)
Table 5. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2015-2020)
Table 6. Global Multiple Sclerosis (MS) Drugs Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Multiple Sclerosis (MS) Drugs Revenue Share by Region (2015-2020)
Table 8. Global Multiple Sclerosis (MS) Drugs Sales (K Pcs) Forecast by Region (2021-2026)
Table 9. Global Multiple Sclerosis (MS) Drugs Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Multiple Sclerosis (MS) Drugs Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Multiple Sclerosis (MS) Drugs Revenue Share Forecast by Region (2021-2026)
Table 12. Global Multiple Sclerosis (MS) Drugs (K Pcs) of Key Companies (2015-2020)
Table 13. Global Multiple Sclerosis (MS) Drugs Sales Share by Company (2015-2020)
Table 14. Global Multiple Sclerosis (MS) Drugs Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Multiple Sclerosis (MS) Drugs Revenue Share by Company (2015-2020)
Table 16. Global Multiple Sclerosis (MS) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Multiple Sclerosis (MS) Drugs as of 2019)
Table 17. Global Multiple Sclerosis (MS) Drugs Average Price (USD/Pcs) of Key Company (2015-2020)
Table 18. Manufacturers Multiple Sclerosis (MS) Drugs Manufacturing Sites and Area Served
Table 19. Manufacturers Multiple Sclerosis (MS) Drugs Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Multiple Sclerosis (MS) Drugs Players
Table 22. Global Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Type (2015-2020)
Table 23. Global Multiple Sclerosis (MS) Drugs Sales Share by Type (2015-2020)
Table 24. Global Multiple Sclerosis (MS) Drugs Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Multiple Sclerosis (MS) Drugs Price (K Pcs) by Type (2015-2020)
Table 26. Global Multiple Sclerosis (MS) Drugs Sales Share by Type (2021-2026)
Table 27. Global Multiple Sclerosis (MS) Drugs Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Multiple Sclerosis (MS) Drugs Revenue Share by Type (2021-2026)
Table 29. Global Multiple Sclerosis (MS) Drugs Price (K Pcs) by Type (2021-2026)
Table 30. Global Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Application (2015-2020)
Table 31. Global Multiple Sclerosis (MS) Drugs Sales Share by Application (2015-2020)
Table 32. Global Multiple Sclerosis (MS) Drugs Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Multiple Sclerosis (MS) Drugs Price (K Pcs) by Application (2015-2020)
Table 34. Global Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Application (2021-2026)
Table 35. Global Multiple Sclerosis (MS) Drugs Sales Share by Application (2021-2026)
Table 36. Global Multiple Sclerosis (MS) Drugs Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Multiple Sclerosis (MS) Drugs Revenue Share by Application (2021-2026)
Table 38. Global Multiple Sclerosis (MS) Drugs Price (K Pcs) by Application (2021-2026)
Table 39. United States Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Company (2015-2020)
Table 40. United States Multiple Sclerosis (MS) Drugs Sales Market Share by Company (2015-2020)
Table 41. United States Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Type (2015-2020)
Table 42. United States Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
Table 43. United States Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Application (2015-2020)
Table 44. United States Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2015-2020)
Table 45. Europe Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Company (2015-2020)
Table 46. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Company (2015-2020)
Table 47. Europe Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Type (2015-2020)
Table 48. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
Table 49. Europe Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Application (2015-2020)
Table 50. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
Table 51. China Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Company (2015-2020)
Table 52. China Multiple Sclerosis (MS) Drugs Sales Market Share by Company (2015-2020)
Table 53. China Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Type (2015-2020)
Table 54. China Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
Table 55. China Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Application (2015-2020)
Table 56. China Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2015-2020)
Table 57. Japan Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Company (2015-2020)
Table 58. Japan Multiple Sclerosis (MS) Drugs Sales Market Share by Company (2015-2020)
Table 59. Japan Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Type (2015-2020)
Table 60. Japan Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
Table 61. Japan Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Application (2015-2020)
Table 62. Japan Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Company (2015-2020)
Table 64. Southeast Asia Multiple Sclerosis (MS) Drugs Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Type (2015-2020)
Table 66. Southeast Asia Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Type (2015-2020)
Table 68. Southeast Asia Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2015-2020)
Table 69. India Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Company (2015-2020)
Table 70. India Multiple Sclerosis (MS) Drugs Sales Market Share by Company (2015-2020)
Table 71. India Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Type (2015-2020)
Table 72. India Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2015-2020)
Table 73. India Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Application (2015-2020)
Table 74. India Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2015-2020)
Table 75. Bayer AG Corporation Information
Table 76. Bayer AG Description and Business Overview
Table 77. Bayer AG Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Bayer AG Multiple Sclerosis (MS) Drugs Product
Table 79. Bayer AG Recent Development
Table 80. Bayhill Therapeutics Corporation Information
Table 81. Bayhill Therapeutics Description and Business Overview
Table 82. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product
Table 84. Bayhill Therapeutics Recent Development
Table 85. Biogen Idec Corporation Information
Table 86. Biogen Idec Description and Business Overview
Table 87. Biogen Idec Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. Biogen Idec Multiple Sclerosis (MS) Drugs Product
Table 89. Biogen Idec Recent Development
Table 90. Cinnagen Corporation Information
Table 91. Cinnagen Description and Business Overview
Table 92. Cinnagen Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. Cinnagen Multiple Sclerosis (MS) Drugs Product
Table 94. Cinnagen Recent Development
Table 95. Daiichi Sankyo Corporation Information
Table 96. Daiichi Sankyo Description and Business Overview
Table 97. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product
Table 99. Daiichi Sankyo Recent Development
Table 100. Eli Lilly Corporation Information
Table 101. Eli Lilly Description and Business Overview
Table 102. Eli Lilly Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. Eli Lilly Multiple Sclerosis (MS) Drugs Product
Table 104. Eli Lilly Recent Development
Table 105. Fast Forward Llc Corporation Information
Table 106. Fast Forward Llc Description and Business Overview
Table 107. Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. Fast Forward Llc Multiple Sclerosis (MS) Drugs Product
Table 109. Fast Forward Llc Recent Development
Table 110. Antisense Therapeutics Corporation Information
Table 111. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 112. Antisense Therapeutics Description and Business Overview
Table 113. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product
Table 114. Antisense Therapeutics Recent Development
Table 115. Apitope Corporation Information
Table 116. Apitope Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 117. Apitope Description and Business Overview
Table 118. Apitope Multiple Sclerosis (MS) Drugs Product
Table 119. Apitope Recent Development
Table 120. Five Prime Therapeutics Corporation Information
Table 121. Five Prime Therapeutics Description and Business Overview
Table 122. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 123. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product
Table 124. Five Prime Therapeutics Recent Development
Table 125. Genmab Corporation Information
Table 126. Genmab Description and Business Overview
Table 127. Genmab Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 128. Genmab Multiple Sclerosis (MS) Drugs Product
Table 129. Genmab Recent Development
Table 130. Artielle Immunotherapeutics Corporation Information
Table 131. Artielle Immunotherapeutics Description and Business Overview
Table 132. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 133. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product
Table 134. Artielle Immunotherapeutics Recent Development
Table 135. Genzyme Corporation Information
Table 136. Genzyme Description and Business Overview
Table 137. Genzyme Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 138. Genzyme Multiple Sclerosis (MS) Drugs Product
Table 139. Genzyme Recent Development
Table 140. Glaxosmithkline Corporation Information
Table 141. Glaxosmithkline Description and Business Overview
Table 142. Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 143. Glaxosmithkline Multiple Sclerosis (MS) Drugs Product
Table 144. Glaxosmithkline Recent Development
Table 145. Gw Pharmaceuticals Corporation Information
Table 146. Gw Pharmaceuticals Description and Business Overview
Table 147. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 148. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product
Table 149. Gw Pharmaceuticals Recent Development
Table 150. Innate Immunotherapeutics Corporation Information
Table 151. Innate Immunotherapeutics Description and Business Overview
Table 152. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 153. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product
Table 154. Innate Immunotherapeutics Recent Development
Table 155. Production Base and Market Concentration Rate of Raw Material
Table 156. Key Suppliers of Raw Materials
Table 157. Multiple Sclerosis (MS) Drugs Distributors List
Table 158. Multiple Sclerosis (MS) Drugs Customers List
Table 159. Multiple Sclerosis (MS) Drugs Market Key Trends
Table 160. Multiple Sclerosis (MS) Drugs Key Opportunities and Drivers
Table 161. Multiple Sclerosis (MS) Drugs Market Challenges
Table 162. Research Programs/Design for This Report
Table 163. Key Data Information from Secondary Sources
Table 164. Key Data Information from Primary Sources
List of Figures
Figure 1. Multiple Sclerosis (MS) Drugs Product Picture
Figure 2. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Multiple Sclerosis (MS) Drugs Market Share by Application in 2020 & 2026
Figure 6. RRMS Examples
Figure 7. SPMS Examples
Figure 8. PPMS Examples
Figure 9. PRMS Examples
Figure 10. Global Multiple Sclerosis (MS) Drugs Sales (K Pcs) Growth Rate (2015-2026)
Figure 11. Global Multiple Sclerosis (MS) Drugs Revenue (US$ Million) Growth Rate (2015-2026)
Figure 12. Global Multiple Sclerosis (MS) Drugs Price Trends Growth Rate (2015-2026) (USD/Pcs)
Figure 13. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region: 2015 VS 2020
Figure 14. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region: 2021 VS 2026
Figure 15. United States Multiple Sclerosis (MS) Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 16. United States Multiple Sclerosis (MS) Drugs Sales (K Pcs) Growth Rate (2015-2026)
Figure 17. Europe Multiple Sclerosis (MS) Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 18. Europe Multiple Sclerosis (MS) Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 19. China Multiple Sclerosis (MS) Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 20. China Multiple Sclerosis (MS) Drugs Sales (Million USD) and Growth Rate (2015-2026)
Figure 21. Japan Multiple Sclerosis (MS) Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 22. Japan Multiple Sclerosis (MS) Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Multiple Sclerosis (MS) Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 24. Southeast Asia Multiple Sclerosis (MS) Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 25. India Multiple Sclerosis (MS) Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 26. India Multiple Sclerosis (MS) Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 27. Global 5 Largest Multiple Sclerosis (MS) Drugs Players Market Share by Revenue in Multiple Sclerosis (MS) Drugs 2015 & 2019
Figure 28. Multiple Sclerosis (MS) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 29. Global Multiple Sclerosis (MS) Drugs Revenue Share by Type (2015-2020)
Figure 30. Global Multiple Sclerosis (MS) Drugs Revenue Growth Rate by Type in 2015 & 2019
Figure 31. Global Multiple Sclerosis (MS) Drugs Revenue Share by Application (2015-2020)
Figure 32. Global Multiple Sclerosis (MS) Drugs Revenue Growth Rate by Application in 2015 & 2019
Figure 33. United States Multiple Sclerosis (MS) Drugs Sales Market Share by Type in 2019
Figure 34. United States Multiple Sclerosis (MS) Drugs Sales Market Share by Type in 2019
Figure 35. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Company in 2019
Figure 36. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Type in 2019
Figure 37. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Application in 2019
Figure 38. China Multiple Sclerosis (MS) Drugs Sales Market Share by Company in 2019
Figure 39. China Multiple Sclerosis (MS) Drugs Sales Market Share by Type in 2019
Figure 40. China Multiple Sclerosis (MS) Drugs Sales Market Share by Application in 2019
Figure 41. Japan Multiple Sclerosis (MS) Drugs Sales Market Share by Company in 2019
Figure 42. Japan Multiple Sclerosis (MS) Drugs Sales Market Share by Type in 2019
Figure 43. Japan Multiple Sclerosis (MS) Drugs Sales Market Share by Application in 2019
Figure 44. Southeast Asia Multiple Sclerosis (MS) Drugs Sales Market Share by Company in 2019
Figure 45. Southeast Asia Multiple Sclerosis (MS) Drugs Sales Market Share by Type in 2019
Figure 46. Southeast Asia Multiple Sclerosis (MS) Drugs Sales Market Share by Application in 2019
Figure 47. India Multiple Sclerosis (MS) Drugs Sales Market Share by Company in 2019
Figure 48. India Multiple Sclerosis (MS) Drugs Sales Market Share by Type in 2019
Figure 49. India Multiple Sclerosis (MS) Drugs Sales Market Share by Application in 2019
Figure 50. Key Raw Materials Price Trend
Figure 51. Manufacturing Cost Structure of Multiple Sclerosis (MS) Drugs
Figure 52. Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs
Figure 53. Multiple Sclerosis (MS) Drugs Industrial Chain Analysis
Figure 54. Channels of Distribution
Figure 55. Distributors Profiles
Figure 56. Porter's Five Forces Analysis
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
全身性硬化症（強皮症）治療薬の世界市場レポート2020 Market Analysis and Insights: Global Systemic Sclerosis Drug Market The global Systemic Sclerosis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Systemic Sclerosis Drug Scope and Market Size The global Systemic Sc…- 多連装ロケットランチャーの世界市場レポート2020 A multiple rocket launcher (MRL) or multiple launch rocket system (MLRS) is a type of rocket artillery system. Rockets have different capabilities than artillery, like longer range, and different payloads, for example considerably larger warheads, or multiple warheads. Unguided rocket artillery is n…
- 血液脳関門輸送薬の世界市場レポート2020 Market Analysis and Insights: Global Blood-Brain Barrier Transport Drugs Market The global Blood-Brain Barrier Transport Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Blood-Brain Barrier Transport Drugs Scope an…
- 麻酔薬・鎮痛薬の世界市場レポート2020 Market Analysis and Insights: Global Anaesthetic Drugs and Pain Drugs Market The global Anaesthetic Drugs and Pain Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Anaesthetic Drugs and Pain Drugs Scope and Market …
- トレプロスチニル薬の世界市場レポート2020 Treprostinil is a vasodilator that is used for the treatment of pulmonary arterial hypertension. North America is the largest consumption place, with a consumption market share nearly 92% in 2018. Following North America, Europe are also very important market with the consumption market share of 6.8…